




PHARMACEUTICAL 2019

CytomX Therapeutics Inc.
Rank 230 of 363





RealRate

PHARMACEUTICAL 2019

CytomX Therapeutics Inc.
Rank 230 of 363



The relative strengths and weaknesses of CytomX Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytomX Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of CytomX Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 0.93% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	445,475
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	97,908
Liabilities, Non-Current	228,317
Other Assets	3,750
Other Compr. Net Income	1.0
Other Expenses	14,303
Other Liabilities	0
Other Net Income	7,573
Other Revenues	59,502
Property and Equipment	6,934
Research and Development	103,866
Selling, General and Administrative Expense	33,510

Output Variable	Value in 1000 USD
Assets	457,108
Liabilities	326,225
Expenses	151,679
Revenues	59,502
Stockholders Equity	130,883
Net Income	-84,604
Comprehensive Net Income	-84,604
Economic Capital Ratio	36%